Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FRAmework-01 in platinum-resistant and platinum-sensitive ovarian cancer
NL-OMON61113Phase 3Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of sofetabart mipitecan, sponsored by Eli Lilly and Company. Started Jul 2026; status: recruiting.
02
Drugs
sofetabart mipitecan
Beyond the preview
Go deeper on NL-OMON61113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61113.